To overview the present global burden of pneumococcal disease is important because new
preventive measures such as the pneumococcal conjugate vaccine 13 are currently being …

Streptococcus pneumoniae can asymptomatically colonize the nasopharynx and cause a
diverse range of illnesses. This clinical spectrum from colonization to invasive …

Background The burden of community-acquired pneumonia (CAP) caused by Streptococcus
pneumoniae (pneumococcus) among adults in Europe is poorly defined. Methods …

Background Ontario, Canada introduced a publicly-funded 13-valent pneumococcal
conjugate vaccine (PCV13) for infants in 2010, replacing the 10-valent (PCV10, 2009–2010) …

This review evaluates the serotype epidemiology of complicated pneumococcal pneumonia
(CPP) during the period 1990–2012. PubMed and EMBASE were searched using the terms …

Abstract Background Infections due to Streptococcus pneumoniae serotypes differ in clinical
manifestations among adults, varying in propensity for severity, invasiveness, and lethality …

Antibiotic-resistant S. pneumoniae is a worldwide problem. The implementation of several
strategies including vaccine campaigns, prudent use of current antibiotics, and programs for …

The Streptococcus pneumoniae polysaccharide capsule plays a role in disease severity. We
assessed the association of serotype with case-fatality ratio (CFR) in invasive pneumococcal …

Pneumococcal serotypes are one of the main determinants of pneumococcal disease
severity; however, data about their implication in respiratory failure are scarce. We …

Objective To determine changes in mortality among adults with invasive pneumococcal
disease (IPD) after introducing pneumococcal conjugate vaccines (PCVs) in children …